Clavis pharma licences thyroid cancer compound
Oslo – Clavis Pharma ASA has signed a licensing deal with US firm Translational Therapeutics, Inc., for the development and commercialization of CP-4033, a patented Lipid Vector Technology (LVT) derivative of ribavirin under preclinical development at Clavis. Under the terms of the agreement, Translational Therapeutics will be responsible for all future development of the drug formulation, which targets the eIF4E oncogene, as a treatment of aggressive thyroid cancer. Additionally, Translational Therapeutics has the option to evaluate the formulation’s potential in other solid tumour indications. Clavis Pharma will receive a minority equity stake in Translational Therapeutics and potential future milestone and royalty payments. Financial terms of the agreement were not disclosed. Preclinical studies with CP-4033 conducted by Translational Therapeutics suggest that CP-4033 may be even more effective than ribavirin at inhibiting eIF4E’s oncogenic activities. Elevated elF4E activity is believed to play a role in about 30% of human cancers.